+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

Solid Tumor Cancer Treatment Market Report 2025 - Product Thumbnail Image

Solid Tumor Cancer Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
From
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Advanced Liver Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Liver Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
AXL Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Advanced Gastric Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Gastric Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Squamous Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Squamous Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
LAG-3 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

LAG-3 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
TIM-3 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

TIM-3 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
Tie-2 Modulators - Pipeline Insight, 2025 - Product Thumbnail Image

Tie-2 Modulators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more